Vaxcyte

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Andrew Guggenhime - President and Chief Financial Officer Grant Pickering - Chief Executive Officer Jim Wassil - Executive Vice President and Chief Operating Officer Jeff Fairman - Vice President, Research Conference Call Participants Jason Gerberry - Bank of America Roger Song - Jefferies David Risinger - SVB Seamus Fernandez - Guggenheim. Jonathan Miller - Evercore Louise Chen - Cantor Joseph Stringer - Needham Operator Good afternoon.

Vaxcyte, Inc. (PCVX) Q4 2022 Earnings Call Transcript

-- Company Received U.S. Food and Drug Administration (FDA) Clearance of VAX-24 Infant Investigational New Drug (IND) Application and Expects to Initiate Phase 2 Study in Second Quarter 2023 -- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-24 Phase 2 Study in Adults 65 and Older on Track for Second Quarter 2023 --

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2 Proof-of-Concept Study Results in Adults, FDA Supported Initiation of Pediatric Program in Infants --

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

Vaxcyte to Present at the SVB Securities Global Biopharma Conference

Affirm

AppLovin Corp

Guardant Health Inc

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Rogers

Rumble Inc

Prometheus Biosciences

Mid-cap stocks are proving to be an attractive investment option over the past few years.

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022

-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenicity Data from VAX-24 Phase 2 Study in Adults 65 and Older Expected in Q2 2023 --

Vaxcyte's VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Altra Industrial Motion

Carvana

Generac Holdings

Maravai LifeSciences Holdings

Norwegian Cruise Line

Olaplex Holdings

PTC Therapeutics

Patterson-UTI Energy

Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.

These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022

-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 --

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in and host one-on-one meetings at the following investor conferences:

Vaxcyte to Present at Upcoming Investor Conferences

Not everything is negative in this bearish market. The healthcare sector is home to stocks with rosy prospects.

Vaxcyte Has A Bright Future Ahead

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

Why Investors Are Suddenly Excited About Vaxcyte

The company released early data for a promising pneumonia vaccine.

Why Shares of Vaxcyte Rose 110.7% This Week

SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 17,812,500 shares of common stock at a public offering price of $32.00 per share and pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $31.999 per underlying share. This includes the exercise in full by the underwriters of their option to purchase up to 2,812,500 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $690.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 15,000,000 shares of common stock and pre-funded warrants to purchase 3,750,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $32.00 per share, and the pre-funded warrants are being sold at a public offering price of $31.999 per underlying share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $600.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Vaxcyte Announces Pricing of $600 Million Public Offering

Vaxcyte, Inc. (PCVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why

SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte (NASDAQ: PCVX ) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. This part of the study handled the safety, tolerability, and immunogenicity of VAX-24.

Why Is Vaxcyte (PCVX) Stock Up 70% Today?

Shares of Vaxcyte Inc. PCVX, -7.42% soared 46.7% in premarket trading on Monday after the company said its experimental 24-valent pneumococcal conjugate vaccine met the primary endpoint in a Phase 1/2 clinical proof-of-concept study. The vaccine was tested in healthy adults.

Vaxcyte's stock rallies 46% on positive data for its pneumococcal vaccine candidate

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards --

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to provide topline results from its Phase 1/2 proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's investigational 24-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged 18-64.

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer as the Company Prepares to Enter Next Phase of Growth -- SAN CARLOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer. Both Mark and Jakub are accomplished industry leaders who bring vast expertise that will support the continued growth and advancement of the Company.

Vaxcyte Expands Executive Leadership Team with Key Appointments

-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 --

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study Expected in October or November 2022 --

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly into Infants --

News for Vaxcyte Stock (PCVX)